Kainos Medicine, Inc. (KOSDAQ:284620)
South Korea
· Delayed Price · Currency is KRW 1,087.00
-105.00 (-8.81%)
At close: Aug 14, 2025
Kainos Medicine Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Net Income | -10,147 | -12,190 | -15,235 | -15,881 | -16,212 | -11,448 | Upgrade
|
| Depreciation & Amortization | 752.53 | 1,152 | 1,277 | 1,262 | 809.72 | 419.68 | Upgrade
|
| Loss (Gain) From Sale of Assets | 3.22 | - | -650.83 | 32.01 | -48.87 | -0.44 | Upgrade
|
| Asset Writedown & Restructuring Costs | 363 | 363 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 689.75 | 719.32 | 65.12 | 535.81 | -125.76 | -1,360 | Upgrade
|
| Loss (Gain) on Equity Investments | 1,827 | 410.11 | - | - | - | - | Upgrade
|
| Stock-Based Compensation | 105.2 | 643.72 | 1,026 | 1,936 | 2,932 | 1,339 | Upgrade
|
| Other Operating Activities | -929.31 | -1,354 | -301.47 | -525.35 | 5,226 | 3,570 | Upgrade
|
| Change in Accounts Receivable | 64.88 | -152.22 | 13.64 | - | - | - | Upgrade
|
| Change in Income Taxes | 33.13 | 67.16 | -85.34 | -23.86 | 14.51 | - | Upgrade
|
| Change in Other Net Operating Assets | 1,539 | 632.54 | -330.41 | 1,368 | -1,791 | -127.69 | Upgrade
|
| Operating Cash Flow | -6,380 | -9,709 | -14,221 | -11,296 | -9,195 | -7,608 | Upgrade
|
| Capital Expenditures | -5.52 | -0.08 | -3,998 | -1,826 | -1,939 | -1,021 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 8,351 | 1.8 | 212.95 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -240.95 | -206.94 | -100 | -639.29 | -456.41 | -199.82 | Upgrade
|
| Investment in Securities | -3,633 | -3,540 | 4,820 | 5,366 | -3,657 | 3,136 | Upgrade
|
| Other Investing Activities | 79.11 | 17.25 | -17.61 | -118.16 | 85.66 | -104.07 | Upgrade
|
| Investing Cash Flow | -2,000 | -4,079 | 9,055 | 2,785 | -5,753 | 1,811 | Upgrade
|
| Short-Term Debt Issued | - | - | 4,900 | 1,246 | - | - | Upgrade
|
| Long-Term Debt Issued | - | - | - | 761.67 | 1,523 | 23,264 | Upgrade
|
| Total Debt Issued | -923.72 | - | 4,900 | 2,008 | 1,523 | 23,264 | Upgrade
|
| Short-Term Debt Repaid | - | - | -5,662 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -587.23 | -2,944 | -20,918 | -362.66 | -257.12 | Upgrade
|
| Total Debt Repaid | -436.41 | -587.23 | -8,605 | -20,918 | -362.66 | -257.12 | Upgrade
|
| Net Debt Issued (Repaid) | -1,360 | -587.23 | -3,705 | -18,910 | 1,161 | 23,007 | Upgrade
|
| Issuance of Common Stock | 5,734 | 1,643 | - | 28,284 | 13,308 | 1,743 | Upgrade
|
| Repurchase of Common Stock | - | - | - | -32.4 | - | - | Upgrade
|
| Other Financing Activities | -0 | -0 | - | - | 197.79 | 1,024 | Upgrade
|
| Financing Cash Flow | 4,374 | 1,056 | -3,705 | 9,342 | 14,667 | 25,775 | Upgrade
|
| Foreign Exchange Rate Adjustments | 54.08 | 229.18 | 256.76 | 890.7 | 1,561 | -1,836 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | 0 | - | - | - | - | 0 | Upgrade
|
| Net Cash Flow | -3,952 | -12,503 | -8,615 | 1,721 | 1,279 | 18,141 | Upgrade
|
| Free Cash Flow | -6,386 | -9,709 | -18,220 | -13,122 | -11,134 | -8,629 | Upgrade
|
| Free Cash Flow Margin | -680.15% | -1644.59% | -6815.87% | -10092.16% | -669.76% | - | Upgrade
|
| Free Cash Flow Per Share | -210.45 | -348.67 | -652.51 | -550.49 | -525.41 | -425.88 | Upgrade
|
| Cash Interest Paid | 0.12 | - | 157.59 | - | - | - | Upgrade
|
| Cash Income Tax Paid | 1.14 | 1.09 | 1.04 | 1.03 | 0.92 | 11.71 | Upgrade
|
| Levered Free Cash Flow | -2,899 | -5,744 | -11,695 | -16,927 | 1,540 | -7,390 | Upgrade
|
| Unlevered Free Cash Flow | -2,876 | -5,714 | -11,547 | -16,083 | 2,588 | -6,913 | Upgrade
|
| Change in Working Capital | 955.05 | 547.48 | -402.1 | 1,344 | -1,776 | -127.69 | Upgrade
|
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.